- Home
- WMK vs DAWN Comparison
WMK vs DAWN Comparison
Compare WMK & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WMK
- DAWN
- Stock Information
- Founded
- WMK 1912
- DAWN 2018
- Country
- WMK United States
- DAWN United States
- Employees
- WMK N/A
- DAWN N/A
- Industry
- WMK Food Chains
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- WMK Consumer Staples
- DAWN Health Care
- Exchange
- WMK Nasdaq
- DAWN Nasdaq
- Market Cap
- WMK 1.7B
- DAWN 1.6B
- IPO Year
- WMK N/A
- DAWN 2021
- Fundamental
- Price
- WMK $70.70
- DAWN $13.34
- Analyst Decision
- WMK
- DAWN Strong Buy
- Analyst Count
- WMK 0
- DAWN 7
- Target Price
- WMK N/A
- DAWN $36.17
- AVG Volume (30 Days)
- WMK 82.6K
- DAWN 1.3M
- Earning Date
- WMK 11-05-2024
- DAWN 10-30-2024
- Dividend Yield
- WMK 1.91%
- DAWN N/A
- EPS Growth
- WMK N/A
- DAWN N/A
- EPS
- WMK 3.56
- DAWN N/A
- Revenue
- WMK $4,759,577,000.00
- DAWN $101,953,000.00
- Revenue This Year
- WMK N/A
- DAWN N/A
- Revenue Next Year
- WMK N/A
- DAWN $44.21
- P/E Ratio
- WMK $19.69
- DAWN N/A
- Revenue Growth
- WMK N/A
- DAWN N/A
- 52 Week Low
- WMK $58.87
- DAWN $11.30
- 52 Week High
- WMK $76.62
- DAWN $18.07
- Technical
- Relative Strength Index (RSI)
- WMK 54.27
- DAWN 38.64
- Support Level
- WMK $68.60
- DAWN $12.86
- Resistance Level
- WMK $74.80
- DAWN $13.71
- Average True Range (ATR)
- WMK 2.36
- DAWN 0.77
- MACD
- WMK -0.16
- DAWN -0.25
- Stochastic Oscillator
- WMK 54.08
- DAWN 12.24
About WMK Weis Markets Inc.
Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products consist of center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.